Johnson & Johnson Continues U.S. Investment with $2 Billion Commitment to Enable Manufacturing at State-Of-The-Art North Carolina Facility

New Brunswick, N.J. – AUGUST 21, 2025 – Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced today it will increase its presence in North Carolina with a 160,000+ square foot dedicated manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment to FUJIFILM over the next 10 years will expand the Company’s U.S. manufacturing capacity and create approximately 120 new jobs in North Carolina.

In the coming months, the Company also intends to share the plans for additional advanced manufacturing facilities in the U.S. as well as the expansion of current U.S. sites. These plans reinforce Johnson & Johnson’s leadership in delivering cutting-edge healthcare solutions and will enable the Company to manufacture the vast majority of our advanced medicines in the U.S. to meet the needs of U.S. patients.

“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”

In March, the Company announced it will invest $55 billion to support U.S. manufacturing, research and development, and technology investments over the next four years.

• Progress continues in the construction of the Wilson, North Carolina facility, which will employ more than 500 people when fully operational and create approximately 5,000 construction jobs during the site development.
• Other investments include extensive R&D infrastructure aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.

Using the facility at the state-of-the-art FUJIFILM site in Holly Springs will allow the Company to further expand its manufacturing capacity in the U.S., and across the U.S., the Company’s investments will support thousands of jobs.

About  Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com .

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.